BNGO vs. AATC, OPXS, AXDX, DAIO, ASTC, PRPO, STAI, TLIS, TBIO, and SMIT
Should you be buying Bionano Genomics stock or one of its competitors? The main competitors of Bionano Genomics include Autoscope Technologies (AATC), Optex Systems (OPXS), Accelerate Diagnostics (AXDX), Data I/O (DAIO), Astrotech (ASTC), Precipio (PRPO), Scantech AI Systems (STAI), Talis Biomedical (TLIS), Telesis Bio (TBIO), and Schmitt Industries (SMIT). These companies are all part of the "measuring and control equipment" industry.
Bionano Genomics vs.
Bionano Genomics (NASDAQ:BNGO) and Autoscope Technologies (NASDAQ:AATC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, community ranking, earnings, profitability, risk, media sentiment and valuation.
Autoscope Technologies has lower revenue, but higher earnings than Bionano Genomics. Bionano Genomics is trading at a lower price-to-earnings ratio than Autoscope Technologies, indicating that it is currently the more affordable of the two stocks.
Bionano Genomics received 162 more outperform votes than Autoscope Technologies when rated by MarketBeat users. Likewise, 64.03% of users gave Bionano Genomics an outperform vote while only 0.00% of users gave Autoscope Technologies an outperform vote.
11.4% of Bionano Genomics shares are owned by institutional investors. 1.6% of Bionano Genomics shares are owned by company insiders. Comparatively, 21.6% of Autoscope Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Bionano Genomics currently has a consensus price target of $90.00, indicating a potential upside of 1,579.10%. Given Bionano Genomics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Bionano Genomics is more favorable than Autoscope Technologies.
Bionano Genomics has a beta of 2.13, suggesting that its share price is 113% more volatile than the S&P 500. Comparatively, Autoscope Technologies has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.
In the previous week, Bionano Genomics' average media sentiment score of 0.00 equaled Autoscope Technologies'average media sentiment score.
Autoscope Technologies has a net margin of 37.59% compared to Bionano Genomics' net margin of -407.34%. Autoscope Technologies' return on equity of 27.06% beat Bionano Genomics' return on equity.
Summary
Autoscope Technologies beats Bionano Genomics on 8 of the 15 factors compared between the two stocks.
Get Bionano Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNGO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bionano Genomics Competitors List
Related Companies and Tools
This page (NASDAQ:BNGO) was last updated on 2/22/2025 by MarketBeat.com Staff
Free BNGO Stock Alerts